Bayer AG Overview
Pro stress-test →Bayer is a German healthcare and agriculture conglomerate where healthcare provides close to half the company's sales including pharmaceutical drugs, vitamins, and consumer healthcare products, while its crop science business sells seeds, pesticides, herbicides, and fungicides. The firm expanded through its 2018 acquisition of Monsanto. The company has a current market capitalization of $47.7B.
Strategic Profile
Pro stress-test →Bayer's stock has recovered significantly, with BofA Securities raising its 12-month price target to €55 from €35 following greater confidence after a U.S. Supreme Court development related to glyphosate litigation. The company projects a return to profit growth from 2026 onwards driven by a robust pharmaceutical pipeline, crop science optimizations, and internal restructuring aimed at significant savings.
Competitive Landscape
Pro stress-test →Bayer competes with multinational pharmaceutical companies including Novartis. In pharmaceuticals, Bayer faces competition from Roche, Merck, and other major pharma firms. In crop science and agricultural inputs, competitors include Corteva Agriscience, BASF, and other specialty chemical companies. Bayer's diversified portfolio across pharmaceuticals, consumer health, and crop science provides competitive advantages in integrated life sciences solutions.
Industry Context
Bayer AG operates in Pharmaceuticals & Agriculture / Life Sciences Conglomerate.
Key facts
Founded: 1863 · Headquarters: Leverkusen, Germany · Employees: 102,000 · Revenue: $50.6B · Market cap: $47.7B